Collaborative, Licensing and Other Arrangements - Novartis - Additional Information (Details) - Collaborative Arrangement [Member] - Novartis [Member] - USD ($) $ in Millions |
3 Months Ended | 6 Months Ended | 12 Months Ended |
|---|---|---|---|
Jun. 30, 2017 |
Jun. 30, 2017 |
Dec. 31, 2015 |
|
| Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] | |||
| Upfront payment received | $ 37.0 | ||
| Eligible milestone payments receivable upon achievement of development, regulatory and commercial milestones | $ 480.0 | ||
| Milestone received under the collaboration agreement | $ 10.0 |
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. No definition available.
|
| X | ||||||||||
- Definition Eligible milestone payments receivable upon achievement of development regulatory and commercial milestones. No definition available.
|
| X | ||||||||||
- Definition Refers to the payment percentage of milestone received under the collaboration agreement. No definition available.
|
| X | ||||||||||
- Definition Proceeds from upfront payment. No definition available.
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|